Navamedic's Virono®: One Tablet to Redefine Cold Sore Treatment

OSLO, Norway – May 22, 2026 – Pharmaceutical company Navamedic ASA today launched a product poised to significantly alter the landscape of self-care for one of the world's most common ailments. Virono®, the first-ever single-dose, over-the-counter (OTC) tablet for recurrent cold sores, is now available in Swedish pharmacies, heralding a new era of convenience for millions of sufferers.

The launch marks a pivotal moment in the consumer health sector, establishing an entirely new treatment category and representing a major step in Navamedic's growth strategy across Northern Europe. This innovative treatment, which has been switched from prescription-only (Rx) status, promises a "one-and-done" solution for an outbreak, a stark contrast to the repetitive applications required by traditional creams and patches.

A New Era for Cold Sore Sufferers

For the vast population affected by cold sores, also known as herpes labialis, the condition is more than a minor inconvenience. Caused by the highly prevalent herpes simplex virus type 1 (HSV-1), outbreaks can be painful, unsightly, and a source of social discomfort. In Sweden alone, an estimated 80 percent of adults carry the virus, and approximately one million people experience three or more outbreaks each year.

Until now, the OTC market has been dominated by topical treatments. Antiviral creams, such as those containing aciclovir or penciclovir, require users to apply the product up to five times a day for several days. While effective at shortening healing time, the need for frequent application can be cumbersome and easy to forget. Hydrocolloid patches, like those from Compeed, offer a more discreet option by covering the sore, but their primary benefit is often seen as concealment rather than accelerated antiviral action.

Virono® enters this market with a fundamentally different approach. It is a single tablet designed to be used just once per outbreak, at the very first sign of the tell-tale tingling or itching that precedes a sore. This shift from a multi-day, multi-application regimen to a single, discreet action represents a significant leap forward in user convenience, addressing a key pain point for those with busy, active lifestyles.

The Science of Convenience: Lauriad® Technology

The innovation behind Virono®'s single-dose efficacy lies in its advanced delivery system. The product is not a pill to be swallowed but a mucoadhesive buccal tablet powered by the patented Lauriad® technology. The small, round tablet is placed on the upper gum, above the incisor tooth, where it adheres and remains in place for several hours.

This unique placement allows the tablet to slowly dissolve, delivering a continuous and localized dose of its active ingredient, 50mg of the proven antiviral drug aciclovir. By releasing the medication directly into the oral cavity, the technology ensures a high concentration of the drug at the site of the viral outbreak—the lips and mouth area. This targeted delivery is more efficient than topical creams, which can be easily wiped or licked off, and it avoids the first-pass metabolism in the liver that occurs with traditional oral pills.

This efficiency is what allows a relatively low 50mg dose of aciclovir to be effective. In contrast, prescription oral antiviral treatments for cold sores often involve much higher systemic doses, sometimes as much as 2 grams in a single day. The Lauriad® technology enables Virono® to achieve its therapeutic effect locally, minimizing systemic exposure while maximizing convenience and efficacy with a single application.

Shaking Up a Crowded Market

Navamedic is launching Virono® into a substantial and growing market. The OTC cold sore treatment sector in just Sweden, Finland, and the Netherlands is valued at approximately NOK 70 million (around EUR 6 million). Globally, the market is projected to reach USD 1.16 billion in 2026 and is expected to grow at a compound annual growth rate of 6.7% over the next several years, driven by the high prevalence of HSV-1 and increasing consumer demand for effective, accessible solutions.

Virono® is positioned not merely as another option but as a category disruptor. Its primary competitive advantage is its unparalleled convenience, a factor that resonates strongly with modern consumer preferences for simplicity and efficiency in healthcare. By eliminating the need for repeated applications and messy creams, Navamedic is betting that Virono® will capture a significant share of the market from established players like GSK, whose Zovirax brand has long been a leader in the topical treatment space.

The move to make a previously prescription-strength approach available over the counter is a critical part of this strategy. It empowers consumers to manage their recurrent condition promptly and effectively without the need for a doctor's visit, which is crucial since antiviral treatments are most effective when started at the earliest signs of an outbreak.

A Strategic Move in Consumer Health

The introduction of Virono® is a calculated and strategic play by Navamedic, aligning perfectly with its ambition to expand its Consumer Health portfolio with differentiated products. The company has identified the Rx-to-OTC switch as a key driver for growth, a trend seen across the European pharmaceutical industry that expands patient access while opening new commercial avenues.

"Virono is a good example of how Rx-to-OTC switches can expand access to clinically proven treatments and create new opportunities within self-care," said Karianne Femtehjell Olsen, Commercial Director Consumer Health & Nutrition at Navamedic, in the company's official announcement. "We are pleased to bring this to the Nordic market and look forward to making it available to a broader consumer base across our markets."

This switch has precedent, as other aciclovir-based products, including combination creams, have successfully transitioned to OTC status in Europe after demonstrating a strong safety and efficacy profile for self-medication. The approval of Virono® suggests regulatory confidence in both the Lauriad® delivery system and the ability of consumers to use the product correctly and safely.

Following its debut in Sweden, Navamedic has already initiated roll-out activities in Finland and has firm plans to launch in the Netherlands later in 2026. This phased regional expansion underscores the company's confidence in Virono®'s potential to become a leading solution for cold sore treatment across key European markets. As consumers increasingly seek greater control over their health with effective and easy-to-use products, Virono® appears well-timed to meet that demand.